anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a myeloma therapeutic agent containing an anti-IL-6 receptor antibody, useful for its use in combination with a nitrogen mustard-based anticancer agent, and capable of improving myeloma therapeutic effect as compared to the case with the use of each of the ingredients singly. SOLUTION: This therapeutic agent contains an anti-IL-6 receptor antibody. A nitrogen mustard-based anticancer agent to be used in combination with the above ingredient is e.g. mechlorethamine, melphalan. The anti-IL-6 receptor antibody, which is pref. PM-1 antibody, a monoclonal antibody of mammal origin, is obtained, for example, by cell fusion of the splenocyte of a mammal immunized with a human-derived IL-6 receptor with myeloma cell to afford a hybridoma which, in turn, is subjected to the aimed production. It is preferable that this therapeutic agent is parenterally administered daily at 0.01-50mg/Kg body weight in terms of the effective dose of the above-mentioned antibody and the nitrogen mustard-based anticancer agent is orally administered.
Plasma and tumoral pharmacokinetics, as well as FDG-PET data will be analyzed to determine the intratumoral and plasma levels of AC480 obtained and its antiproliferative activity. After recovery from surgery, all patients will resume AC480 at 300 mg orally BID until evidence of disease progression or toxicity (Part II: Maintenance Therapy). Those patients will be followed for determination of 6-month progression free survival. Patients will remain on treatment for as long as they have clinical benefit from the treatment. There will be no limit to the number of cycles of treatment a patient can receive providing they continue to benefit from and are not intolerant to AC480 administration.

The data collected in this study will be summarized in tables listing the mean, standard deviation, and number of patients for continuous data, or in tables listing count and percentage for categorical data, where appropriate. All patient data will be listed by patient or by parameter, all statistical analyses will be performed and all data appendices will be created by using the SAS system. Pharmacokinetic analysis will be made to determine if AC480 reaches the intracerebral tumor tissue. Comparisons will be made between the data obtained from the plasma of the same patients treated on AC480, including determination of the tumor-to-plasma ratio. The most common side effects of AC480 are generally mild to moderate in severity and include: nausea, vomiting, diarrhea, fatigue, cough, elevation of the liver enzymes, anemia, and rash.
The nasogastric tube (NGT) is an essential element of our daily clinical practice, commonly used for the administration of enteral nutrition and medication or for gastric decompression and diagnostic procedures. Despite its common use, it is still an invasive procedure with potential complications. Ultrasound is a noninvasive, inexpensive, widely available and rapid method that can speed up the proper verification of these devices. The main objective of this study is to evaluate whether the use of ultrasound as a method of checking the normal positioning of the NGT is reliable, without requiring other diagnostic tests. Clinical trial that will include patients who had the NGT placed intraoperatively. 114 patients (57 with NGT and 57 without NGT) will be examined by ultrasound in the immediate postoperative period to diagnose the normal positioning of the NGT or its absence. Patients who have had the NGT placed will have had their NGT placed correctly by chest X-ray. The upper part of the patient will be covered for the examiner, who will only have access to the patient's abdomen and will not know which patients have NGT or not.
Obsessive-compulsive disorder (OCD) is a common, chronic, and oftentimes disabling disorder. The only established first-line treatments for OCD are a specific form of Cognitive Behavioral Therapy (CBT) and the Serotonin Reuptake Inhibitors (SRIs). Few patients with OCD experience complete symptom resolution with either modality. Even after two consecutive adequate SRI trials, as many as 30%-40% of patients fail to derive a satisfactory response. Pharmacological options for these SRI-resistant cases include switching to a different antidepressant, increasing the dose of SRI, or augmentation with another agent.

Among the pharmacological augmentation strategies, adjunctive antipsychotic medications enjoy the most empirical support as well as wide-scale use in clinical practice. Utilizing IMS Health's National Disease and Therapeutic Index (NDTI) for 12 months ending in November 2004, 4.2% of antipsychotic medication use is for anxiety and 1.3% specifically for OCD. Conversely, for OCD patients, antipsychotic medications account for 8.6% of drug use (IMS Health NDTI MAT, 2004). Among pediatric patients, prescriptions of antipsychotics increased from 8.6 out of 1,000 U.S. children in 1995-1996 to 39.4 out of 1,000 children in 2001-2002 (Cooper et al., 2006). Similarly, Medco, a private insurance company, noted that the rate of children 19 years and under covered by private insurance with at least one atypical prescription jumped 80% from 2001 to 2005 - from 3.6 per 1,000 to 6.5 per 1,000 (USA Today, extracted 5/2/2006). These rates parallel our own research, in which approximately 35% of adult patients on psychotropics were taking an antipsychotic in addition to their SRI. Thus, clearly there is a large sample of OCD patients that are being prescribed atypical antipsychotics to augment other treatments.

Previous studies showed that approximately 33-50% of OCD patients who have not had an adequate response to SRI medication had a positive response when an atypical antipsychotic medication was added (Bloch et al., 2006). Risperidone has been the most studied agent and has the most consistently positive findings (e.g., McDougle et al., 2000). However, the problematic acute and long-term side effects of risperidone (and other atypicals) are of concern and, at times, limit their use. Paliperidone, a metabolite of risperidone that utilizes OROS osmotic drug-release technology, has a number of advantages over risperidone including a lack of drug x drug interactions and a predictable pharmacokinetic profile that is associated with better tolerability. Thus, paliperidone has the potential to be a safer alternative for augmentation in OCD patients pending supporting efficacy data. Given the need to examine the efficacy of paliperidone, this protocol is designed to determine whether paliperidone augmentation of an SRI is effective relative to a placebo-control, and safe/tolerable in patients with OCD who have not adequately responded to past adequate SRI treatment.
The present invention relates to a preparation technology and a production method for an integrated new formulation of a belamcanda rhizome and ephedra decoction, wherein the raw materials of active ingredients comprise: 9 parts by weight of belamcanda rhizome, 9 parts by weight of ephedra, 9 parts by weight of ginger, 3 parts by weight of asarum, 6 parts by weight of aster root, 6 parts by weight of common coltsfoot flower, 3 parts by weight of jujube, 9 parts by weight of pinellia rhizome, and 3 parts by weight of schisandra fruit. The production process of the integrated new formulation comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of belamcanda rhizome and ephedra decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of belamcanda rhizome and ephedra decoction can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of belamcanda rhizome and ephedra decoction can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
Patients accepted regional citrate anticoagulation for CRRT. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L. Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+. Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level.
PURPOSE: To obtain a skin external agent for beautifully whitening the skin, enhanced in the percutaneous and cell membrane permeability of glucosamine having a beautifully whitening effect, and effective for improving chromatodermatosis by compounding phosphatidyl glucosamine and lysophosphatidyl glucosamine. CONSTITUTION: This skin external agent for beautifully whitening the skin contains 0.001-20wt.% of one or more kinds of compounds of formula I [A is group of formula II (R1 , R2 are each a fatty acid residue), etc.; B is group of formula III; M is H, an alkali metal, an alkaline earth metal] as an active ingredient. The compound of formula I has good percutaneous permeability and good cell membrane permeability, and can well arrive at melanocytes existing mainly in a skin basal layer and inhibit the activity or biosynthesis of tyrosinase to well prevent the production of melanin. The compound of formula I can prevent chromatodermatosis caused by stains, freckles or sunburn in a small compounding amount, does not cause problems such as skin irritation, and is stable in the form of the preparation.  The skin external agent can be prepared in the forms of lotions, gels, emulsions, ointments, etc.
An apparatus for medication management, comprising: a housing for a package for a medicament; a sensor coupled to the housing for sensing whether the package has been removed or is likely to have been removed from the housing; and a transmitter for wirelessly transmitting data regarding the readings of the sensors to a remote computer. A system for medication management is provided that communicates with a device for medication management. The remote computer is configured to send an alarm to the external device, and the alarm is based on the readings of the sensor. Further, an apparatus for medication management includes: a housing for a medicament; and a sensor for sensing the amount of the drug within the housing. The sensor includes a plurality of conductive electrodes arranged in a staggered pattern and provided in a substantially horizontal position. Related systems, methods, techniques, and articles are also described.
An increasing amount of evidence from evidence-based medicine suggests that early rehabilitation intervention (including early active and passive exercises, position management, pulmonary rehabilitation, etc.) for mechanical ventilation patients is safe and feasible, and can promote certain degree of functional recovery and reduce the length of stay in the intensive care unit (ICU). However, the differences in consciousness state, muscle strength, respiratory function, and activity of daily living (ADL) among patients who are discharged from the ICU after condition stabilization are very large, even some patients did not obtain obvious benefits. Therefore, how to identify which patients may have better benefit from early rehabilitation intervention is a key issue that needs to be focused on in ICU.

This study used "Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD)" as the guideline. Survivors undergoing mechanical ventilation in the ICU were recruited as the participants, whether patients gained progress in ADL function at different time points after receiving early rehabilitation intervention in the ICU was used as the outcome which is a time-to-event indicator. Demographic data, clinical diagnostic data and disease intervention data of the subjects were collected as alternative predictors. Variable transformation and variable screening were used to find predictors that could predict the outcome. The process of constructing clinical predictive models is completed by fitting models through regression equations and machine learning algorithms, internal validation, external validation, and clinical value assessment. The model with the best prediction efficiency is selected based on the differentiation and calibration of different models after validation. This model will be presented with a nomogram or a web app. The application of this clinical predictive model will identify whether and when this patient can received better recovery on ADL after receiving early rehabilitation intervention, so as to further optimize the timing of early intervention in rehabilitation and improve his survival quality.
Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
Nitrite exposure has become a significant concern in the aquaculture industry, posing a severe threat to aquatic animals such as shrimp. While studies have reported the adverse effects of nitrite on shrimp growth, the part played by the gut microbiota in shrimp mortality resulting from nitrite exposure is poorly understood. Here, the effects of nitrite on shrimp gut bacterial community were investigated using 16S rRNA amplicon sequencing, bacterial isolation, genomic analysis, and infection experiments. Compared to the control_healthy group, changes in the bacterial composition of the nitrite_dead group were associated with reduced abundance of specific beneficial bacteria and increased abundance of certain pathogenic bacteria. Notably, members of the Photobacterium genus were found to be significantly enriched in the nitrite_dead group. Genomic analysis of a representative Photobacterium strain (LvS-8n3) revealed a variety of genes encoding bacterial toxins, including hemolysin, adhesin, and phospholipase. Furthermore, it was also found that LvS-8n3 exhibits strong pathogenicity, probably due to its high production of pathogenic factors and the ability to utilize nitrite for proliferation. Therefore, the proliferation of pathogenic Photobacterium species appears pivotal for driving shrimp mortality caused by nitrite exposure. These findings provide novel insights into the disease mechanism in shrimp under conditions of environmental change.
Doxorubicin 25 mg/m²/day over 12 hrs on days 1-3, Dactinomycin 45 µg/kg/day (max. 2 mg), i.v. on day 1, and Cisplatin 70 mg/m²/d over 6 hrs on day 4, and Vincristine 1.5 mg/m²/day (max. 2 mg), i.v. on days 8, 15. An identical second cycle is started on day 28 if the side effects allow it. The further treatment is identical to the standard arm with four more cycles of chemotherapy following radiation in some of the patients in all treatment arms.
Subglottic HFJV is performed through the LaserJet catheter. It is characterized by the delivery of small tidal volumes from a high pressure jet at very high frequencies (100-400) followed by passive expiration for a very short period before delivering the next jet, creating an "auto-PEEP".
<P>PROBLEM TO BE SOLVED: To provide a face mask for preventing the saggy face by tightening the skin of the face through raising up the cheek line from the mouth side, of which decay causes the sagging or the wrinkles of the skin of the face.  <P>SOLUTION: The face mask to be put on the face is formed of a stretch fabric. The mask body is right/left symmetrically formed and provided with a pair of main belts to be fastened around the rear of the top and a pair of assisting belts to be fastened around the back of the head. The ends of the belts are engaging-retained by a hook-and-loop fastener, respectively. The mask has ear-holes in the ear positions of the face, a mouth hole in the mouth position, a chin hole below the mouth and a rubber band provided on a lower edge of the jaw position of the mask.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Participants in this arm will continue their usual care for fatigue. The therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their fatigue. The study therapist will emphasize the importance of completing the outcome assessments. Following the completion of their final assessment (3 month follow-up); these individuals will be offered their choice of the two hypnosis treatments.
Introduction: The 21-gene analysis (OncotypeDX) is validated test for pT1-3, pN0-1 with hormone receptor (HR) positive and normal expression of human epidermal growth factor receptor-2 (HER2) breast cancer (BC) to determine the aggressiveness of the disease based on the calculation of Recurrence Score (RS). Methods: In this retrospective study the authors correlated pathological characteristics and Recurrence Score (RS) by traditional statistical methods and Observed Oriented Modeling (OOM) in a realistic cohort of BC patients. Results: OncotypeDX tests were performed in 94 tumour specimens of 90 BC patients. >83% of node-negative (pN0) and >72% of node-positive (pN1) cases could avoid chemotherapy. For pN0 cases, non-parametric correlation and tests demonstrated significant association in eight types of characteristics [progesterone receptor (PR) expression, Ki-67 value, Ki-67 group, PR group, grade, estrogen receptor (ER) expression, Nottingham Prognostic Index (NPI) and Clinical Risk]. For pN1 cases, parametric correlation and tests showed significant association in six characteristic types (number of positive nodes, ER and PR expression, PR group, Ki-67 group and NPI). Based on OOM for pN0 cases, significant associations were established in three characteristics (Ki-67 group, grade and NPI group). For pN1 cases OOM found significant associations in seven characteristics (PR group, PNI, LVI, Ki-67 group, grade, NPI group and number of positive nodes). Conclusion: First in oncology, OOM was applied, which found some other significant characteristics associated with RS than traditional statistical methods. There were few patients, where no clinical associations were found between characteristics and RS contrary to statistically significant differences. Therefore, the results of these statistical analyses can be neither applied for individual cases nor able to provide the bases for screening patients, i.e., whether they need for OncotypeDX testing or not. OncotypeDX still provides a personalised approach in BC.
Children will be followed for four weeks (3 to 5 weeks) after the inclusion in the study. Parents will complete the TRACK questionnaire in both visit and will answer additional questions about respiratory symptoms and use of medication.
Women with the extremely prevalent polycystic ovary syndromegather multiple cardiovascular risk factors and chronic subclinical inflammation. Interactions between diet, adiposity, and gut microbiota modulate intestinal permeabilityand bacterial product translocation, and may contribute to the chronic inflammation process associated with the polycystic ovary syndrome. In the present study, we aimed to address the effects of obesity, functional hyperandrogenism, and diverse oral macronutrients on intestinal permeabilityby measuring circulating markers of gut barrier dysfunction and endotoxemia. Participants included 17 non-hyperandrogenic control women, 17 women with polycystic ovary syndrome, and 19 men that were submitted to glucose, lipid, and protein oral loads. Lipopolysaccharide-binding protein, plasma soluble CD14, succinate, zonulin family peptide, and glucagon-like peptide-2 were determined at fasting and after oral challenges. Macronutrient challenges induced diverse changes on circulating intestinal permeabilitybiomarkers in the acute postprancial period, with lipids and proteins showing the most unfavorable and favorable effects, respectively. Particularly, lipopolysaccharide-binding protein, zonulin family peptide, and glucagon-like peptide-2 responses were deregulated by the presence of obesity after glucose and lipid challenges. Obese subjects showed higher fasting intestinal permeabilitybiomarkers levels than non-obese individuals, except for plasma soluble CD14. The polycystic ovary syndromeexacerbated the effect of obesity further increasing fasting glucagon-like peptide-2, lipopolysaccharide-binding protein, and succinate concentrations. We observed specific interactions of the polycystic ovary syndromewith obesity in the postprandial response of succinate, zonulin family peptide, and glucagon-like peptide-2. In summary, obesity and polycystic ovary syndromemodify the effect of diverse macronutrients on the gut barrier, and alsoinfluence intestinal permeabilityat fasting,contributing to the morbidity of functional hyperandrogenism by inducing endotoxemia and subclinical chronic inflammation.
1,161,492. Herbicides containing fluoropyridines. IMPERIAL CHEMICAL INDUSTRIES Ltd. 9 Aug., 1966 [19 Aug., 1965]; No. 33064/66. Divided out of 1161491. Heading ASE. [Also in Division C2] The invention comprises an agriculturally useful composition comprising as active ingredient a compound of the general formula or a salt thereof, where R 3  and R 5 , which may be the same or different, are atoms of chlorine or fluorine, and R 4  and R 6 , which may be the same or different, represent atoms of fluorine or chlorine or an unsubstituted, or substituted, alkyl, alkenyl, alkoxy, aryl, alkaryl, aryloxy, hydroxy, carboxyl or functional derivative thereof (as defined below), acyl (as defined below), acyloxy, mercapto, acylthio, sulpho, amino, hydrazine, amide, amidine, azide, ureide, carbamoyl, nitro, cyano, or heterocyclic groups, provided that when R 4 . is a hydroxy, acyloxy, acylthio, mercapto, or substituted mercapto group R 6  is not an atom of fluorine or chlorine; and when R 6  is a hydroxyl group R 4  is not a fluorine or chlorine atom; and a carrier for the active ingredient comprising a solid diluent, or a liquid diluent containing a surface active agent. The term "aryl" denotes the groups -CO.X, -SO.X, -SO 2 .X. and -P(=)XZ where Y is oxygen or sulphur and X and Z are monovalent organic hydrocarbon or substituted hydrocarbon groups. The term "functional derivative" denotes a salt or an ester of a carboxyl group. Specified solid diluents are powdered kaolin, Fuller's earth, gypsum, chalk, Hewitt's earth and china clay. The preferred liquid diluent is water, and in these compositions the active ingredient is present as solid particles or as droplets of a solution of the active ingredient in a water insoluble solvent. These waterbased compositions may be obtained by dilution or dispersion of a concentrate, the concentrate being (a) an aqueous dispersion of the active ingredient and containing a surface active agent and a suspending agent, (b) a wettable powder containing the active ingredient and a solid surface-active agent with or without additional solid diluent, or (c) a solution of the active ingredient, with or without a surface-active agent, in an organic solvent. The compositions may contain additional active ingredients, paraquat and diquat being specified. The compositions may be employed as pre- or post-emergence herbicides, and are also stated to exhibit pesticidal, fungicidal, nematocidal and plant growth regulating activity.